ny-eso-1 and melan-a/mart-1 peptides
Vaccineexperimental
Clinical trial activity
1 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2015 (NCT02334735)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ny-eso-1 and melan-a/mart-1 peptides
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02334735 | Phase 2 | Jul 1, 2015 | Cornell University, Icahn School of Medicine at Mount Sinai, Ludwig Institute for Cancer Research, Melanoma Research Alliance, New York University, Oncovir, Inc. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cornell University | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Icahn School of Medicine at Mount Sinai | Academic/Hospital | 1 | 1 | 1 | 2015 |
| Ludwig Institute for Cancer Research | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Melanoma Research Alliance | Academic/Hospital | 1 | 0 | 1 | 2015 |
| New York University | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Oncovir, Inc. | For profit | 1 | 0 | 1 | 2015 |
6 organizations
Page 1 / 1